IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment.
Adenocarcinoma
IL-32
Lung cancer
Macrophage
Tumor microenvironment
Journal
Medical molecular morphology
ISSN: 1860-1499
Titre abrégé: Med Mol Morphol
Pays: Japan
ID NLM: 101239023
Informations de publication
Date de publication:
06 Feb 2024
06 Feb 2024
Historique:
received:
23
10
2023
accepted:
23
12
2023
medline:
6
2
2024
pubmed:
6
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
Interleukin 32 (IL-32) is a proinflammatory cytokine secreted from several kinds of cancer cells. In the present study, we investigated the significance of IL-32 in lung adenocarcinoma by immunohistochemistry and bioinformatics analysis. IL-32 was positive in cancer cells of 21 cases (9.2%) of total 228 cases. Increased IL-32 gene expression was linked to worse clinical course in TCGA analysis, however, IL-32 expression in immunohistochemistry was not associated to clinical course in our cohort. It was also found that high IL-32 expression was seen in cases with increased lymphocyte infiltration. In vitro studies indicated that IFN-γ induced gene expression of IL-32 and PD1-ligands in lung adenocarcinoma cell lines. IL-32, especially IL-32β, also induced overexpression of PD1-ligands in human monocyte-derived macrophages. Additionally, Cancer-cell-derived IL-32 was elevated by stimulation with anticancer agents. In conclusion, IL-32 potentially induced by inflammatory conditions and anticancer therapy and contribute to immune escape of cancer cells via development the immunosuppressive microenvironment. IL-32 might be a target molecule for anti-cancer therapy.
Identifiants
pubmed: 38316697
doi: 10.1007/s00795-023-00378-5
pii: 10.1007/s00795-023-00378-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science London
ID : 20H03459
Informations de copyright
© 2024. The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.
Références
Bade BC, Dela Cruz CS (2020) Lung Cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1–24
doi: 10.1016/j.ccm.2019.10.001
pubmed: 32008623
Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 28:1563–1579
doi: 10.1158/1055-9965.EPI-19-0221
pubmed: 31575553
pmcid: 6777859
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185
doi: 10.1016/j.addr.2015.11.009
pubmed: 26621196
Pittet MJ, Michielin O, Migliorini D (2022) Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol 19:402–421
doi: 10.1038/s41571-022-00620-6
pubmed: 35354979
Matsubara E, Yano H, Pan C, Komohara Y, Fujiwara Y, Zhao S, Shinchi Y, Kurotaki D, Suzuki M (2023) The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages. Cancers (Basel) 15:2250
doi: 10.3390/cancers15082250
pubmed: 37190178
Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, Yoshii D, Yonemitsu K, Fujiwara Y, Ikeda K, Tamada K, Sakagami T, Suzuki M (2022) The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother 71:2645–2661
doi: 10.1007/s00262-022-03187-4
pubmed: 35352168
pmcid: 8963674
Matsubara E, Shinchi Y, Komohara Y, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzuki M (2023) PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol 56:250–256
doi: 10.1007/s00795-023-00361-0
pubmed: 37402054
Osman A, Bhuyan F, Hashimoto M, Nasser H, Maekawa T, Suzu S (2014) M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages. J Immunol 192:5083–5089
doi: 10.4049/jimmunol.1302732
pubmed: 24748497
Nasser H, Takahashi N, Eltalkhawy YM, Reda O, Lotfi S, Nasu K, Sakuragi JI, Suzu S (2022) Inhibitory and stimulatory effects of IL-32 on HIV-1 Infection. J Immunol 209:970–978
doi: 10.4049/jimmunol.2200087
pubmed: 36130125
Shinchi Y, Komohara Y, Yonemitsu K, Sato K, Ohnishi K, Saito Y, Fujiwara Y, Mori T, Shiraishi K, Ikeda K, Suzuki M (2019) Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: a retrospective study by double immunohistochemistry. Cancer Sci 110:2711–2721
doi: 10.1111/cas.14128
pubmed: 31294893
pmcid: 6726681
Nakagawa T, Ohnishi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y (2017) Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop 57:31–36
doi: 10.3960/jslrt.17017
pubmed: 28679964
pmcid: 6144271
Saito Y, Fujiwara Y, Shinchi Y, Mito R, Miura Y, Yamaguchi T, Ikeda K, Urakami S, Nakashima Y, Sakagami T, Suzuki M, Tabata Y, Komohara Y (2022) Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Sci 113:3255–3266
doi: 10.1111/cas.15442
pubmed: 35633190
pmcid: 9459416
Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704
doi: 10.1111/cas.13065
pubmed: 27564404
pmcid: 5132271
Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L, Wang Q (2014) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65:24–32
doi: 10.1016/j.cyto.2013.09.017
pubmed: 24140068
Sorrentino C, Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180:769–779
doi: 10.1164/rccm.200903-0400OC
pubmed: 19628777
Okimoto T, Kotani H, Iida Y, Koyanagi A, Tanino R, Tsubata Y, Isobe T, Harada M (2020) Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer Sci 111:1910–1920
doi: 10.1111/cas.14401
pubmed: 32232903
pmcid: 7293070
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH (2017) Interleukin 32, inflammation and cancer. Pharmacol Ther 174:127–137
doi: 10.1016/j.pharmthera.2017.02.025
pubmed: 28223235
Park MH, Yoon DY, Ban JO, Kim DH, Lee DH, Song S, Kim Y, Han SB, Lee HP, Hong JT (2015) Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32beta overexpressed transgenic mice. Oncotarget 6:38566–38577
doi: 10.18632/oncotarget.6160
pubmed: 26497686
pmcid: 4770721
Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY, Yoon DY (2009) A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 128:e532–e540
doi: 10.1111/j.1365-2567.2008.03025.x
pubmed: 19740314
pmcid: 2753893
Hough JT, Zhao L, Lequio M, Heslin AJ, Xiao H, Lewis CC, Zhang J, Bai Q, Wakefield MR, Fang Y (2023) IL-32 and its paradoxical role in neoplasia. Crit Rev Oncol Hematol 186:104011
doi: 10.1016/j.critrevonc.2023.104011
pubmed: 37105370
Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F (2020) Regulation of PD-L1 expression by NF-kappaB in cancer. Front Immunol 11:584626
doi: 10.3389/fimmu.2020.584626
pubmed: 33324403
pmcid: 7724774
Lei J, Xu F, Deng C, Nie X, Zhong L, Wu Z, Li J, Wu X, He S, Chen Y (2023) Fusobacterium nucleatum promotes the early occurrence of esophageal cancer through upregulation of IL-32/PRTN3 expression. Cancer Sci 114:2414–2428
doi: 10.1111/cas.15787
pubmed: 36919771
pmcid: 10236610
Sun Y, Qian Y, Chen C, Wang H, Zhou X, Zhai W, Qiu L, Zhou X, Ning H, Zhao Y, Shi C, Han L, Qi Y, Wu Y, Gao Y (2022) Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. J Exp Clin Cancer Res 41:145
doi: 10.1186/s13046-022-02348-8
pubmed: 35428295
pmcid: 9013041